Caricamento...
Tumor Mutational Burden, Toxicity and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-Regression Analysis
PURPOSE: Tumor mutational burden (TMB) has emerged as a potential predictive biomarker for clinical response to ICI therapy, but whether TMB also predicts toxicity remains unknown. We investigated the relationship between TMB, objective response rate (ORR), overall survival (OS), and toxicity for IC...
Salvato in:
| Pubblicato in: | Clin Cancer Res |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501151/ https://ncbi.nlm.nih.gov/pubmed/32586938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0458 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|